FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2125222022> ?p ?o ?g. }

• W2125222022 abstract "Background Long‐acting bronchodilators, comprising long‐acting beta2‐agonists (LABA) and long‐acting anti‐muscarinic agents (LAMA, principally tiotropium), are commonly used for managing persistent symptoms of chronic obstructive pulmonary disease (COPD). Combining these treatments, which have different mechanisms of action, may be more effective than the individual components. However, the benefits and risks of combining tiotropium and LABAs for the treatment of COPD are unclear. Objectives To compare the relative effects on markers of quality of life, exacerbations, symptoms, lung function and serious adverse events in people with COPD randomised to LABA plus tiotropium versus tiotropium alone; or LABA plus tiotropium versus LABA alone. Search methods We searched the Cochrane Airways Group Specialised Register of trials and ClinicalTrials.gov up to July 2015. Selection criteria We included parallel‐group, randomised controlled trials of three months or longer comparing treatment with tiotropium in addition to LABA against tiotropium or LABA alone for people with COPD. Data collection and analysis Two review authors independently assessed trials for inclusion and then extracted data on trial quality and the outcome results. We contacted study authors for additional information. We collected information on adverse effects from the trials. Main results This review included 10 trials on 10,894 participants, mostly recruiting participants with moderate or severe COPD. All of the trials compared tiotropium in addition to LABA to tiotropium alone, and four trials additionally compared LAMA plus LABA with LABA alone. Four studies used the LABA olodaterol, three used indacaterol, two used formoterol, and one used salmeterol. Compared to tiotropium alone, treatment with tiotropium plus LABA resulted in a slightly larger improvement in mean health‐related quality of life (St George's Respiratory Questionnaire (SGRQ) (mean difference (MD) ‐1.34, 95% confidence interval (CI) ‐1.87 to ‐0.80; 6709 participants; 5 studies). The MD was smaller than the four units that is considered clinically important, but a responder analysis indicated that 7% more participants receiving tiotropium plus LABA had a noticeable benefit (greater than four units) from treatment in comparison to tiotropium alone. In the control arm in one study, which was tiotropium alone, the SGRQ improved by falling 4.5 units from baseline and with tiotropium plus LABA the improvement was a fall of a further 1.3 units (on average). Most of the data came from studies using olodaterol. High withdrawal rates in the trials increased the uncertainty in this result, and the GRADE assessment for this outcome was therefore moderate. There were no significant differences in the other primary outcomes (hospital admission or mortality). The secondary outcome of pre‐bronchodilator forced expiratory volume in one second (FEV1) showed a small mean increase with the addition of LABA over the control arm (MD 0.06, 95% CI 0.05 to 0.07; 9573 participants; 10 studies), which showed a change from baseline ranging from 0.03 L to 0.13 L with tiotropium alone. None of the other secondary outcomes (exacerbations, symptom scores, serious adverse events, and withdrawals) showed any statistically significant differences between the groups. There was moderate heterogeneity for both exacerbations and withdrawals. This review included data on four LABAs: two administered twice daily (salmeterol, formoterol) and two once daily (indacaterol, olodaterol). The results were largely from studies of olodaterol and there was insufficient information to assess whether the other LABAs were equivalent to olodaterol or each other. Comparing LABA plus tiotropium treatment with LABA alone, there was a small but significant improvement in SGRQ (MD ‐1.25, 95% CI ‐2.14 to ‐0.37; 3378 participants; 4 studies). The data came mostly from studies using olodaterol and, although the difference was smaller than four units, this still represented an increase of 10 people with a clinically important improvement for 100 treated. There was also an improvement in FEV1 (MD 0.07, 95% CI 0.06 to 0.09; 3513 participants; 4 studies), and in addition an improvement in exacerbation rates (odds ratio (OR) 0.80, 95% CI 0.69 to 0.93; 3514 participants; 3 studies). Authors' conclusions The results from this review indicated a small mean improvement in health‐related quality of life and FEV1 for participants on a combination of tiotropium and LABA compared to either agent alone, and this translated into a small increase in the number of responders on combination treatment. In addition, adding tiotropium to LABA reduced exacerbations, although adding LABA to tiotropium did not. Hospital admission and mortality were not altered by adding LABA to tiotropium, although there may not be enough data. While it is possible that this is affected by higher attrition in the tiotropium group, one would expect that participants withdrawn from the study would have had less favourable outcomes; this means that the expected direction of attrition bias would be to reduce the estimated benefit of the combination treatment. The results were largely from studies of olodaterol and there was insufficient information to assess whether the other LABAs were equivalent to olodaterol or each other." @default.
• W2125222022 created "2016-06-24" @default.
• W2125222022 creator A5029606237 @default.
• W2125222022 creator A5065716950 @default.
• W2125222022 date "2015-10-22" @default.
• W2125222022 modified "2023-10-17" @default.
• W2125222022 title "Long-acting beta₂ -agonist in addition to tiotropium versus either tiotropium or long-acting beta₂ -agonist alone for chronic obstructive pulmonary disease" @default.
• W2125222022 cites W1483376681 @default.
• W2125222022 cites W1498865317 @default.
• W2125222022 cites W1501843833 @default.
• W2125222022 cites W1528779133 @default.
• W2125222022 cites W1548909672 @default.
• W2125222022 cites W1597616964 @default.
• W2125222022 cites W1598761580 @default.
• W2125222022 cites W1631769030 @default.
• W2125222022 cites W1747716890 @default.
• W2125222022 cites W1950113648 @default.
• W2125222022 cites W1964916010 @default.
• W2125222022 cites W1972154367 @default.
• W2125222022 cites W1980789906 @default.
• W2125222022 cites W1985410360 @default.
• W2125222022 cites W1990268336 @default.
• W2125222022 cites W1990601323 @default.
• W2125222022 cites W1996849150 @default.
• W2125222022 cites W1997094772 @default.
• W2125222022 cites W1998480220 @default.
• W2125222022 cites W2003293665 @default.
• W2125222022 cites W2016593979 @default.
• W2125222022 cites W2026247098 @default.
• W2125222022 cites W2043295697 @default.
• W2125222022 cites W2047810933 @default.
• W2125222022 cites W2048018030 @default.
• W2125222022 cites W2051719749 @default.
• W2125222022 cites W2055130738 @default.
• W2125222022 cites W2056303817 @default.
• W2125222022 cites W2060873423 @default.
• W2125222022 cites W2063737424 @default.
• W2125222022 cites W2072038990 @default.
• W2125222022 cites W2073757316 @default.
• W2125222022 cites W2075468465 @default.
• W2125222022 cites W2080505657 @default.
• W2125222022 cites W2081226017 @default.
• W2125222022 cites W2082855236 @default.
• W2125222022 cites W2085717270 @default.
• W2125222022 cites W2091670398 @default.
• W2125222022 cites W2094495786 @default.
• W2125222022 cites W2095052694 @default.
• W2125222022 cites W2100389803 @default.
• W2125222022 cites W2101932319 @default.
• W2125222022 cites W2104636056 @default.
• W2125222022 cites W2105234929 @default.
• W2125222022 cites W2111143045 @default.
• W2125222022 cites W2120356269 @default.
• W2125222022 cites W2123850585 @default.
• W2125222022 cites W2127162896 @default.
• W2125222022 cites W2127789103 @default.
• W2125222022 cites W2128643475 @default.
• W2125222022 cites W2132192372 @default.
• W2125222022 cites W2134820467 @default.
• W2125222022 cites W2141034778 @default.
• W2125222022 cites W2142430815 @default.
• W2125222022 cites W2142449488 @default.
• W2125222022 cites W2142724633 @default.
• W2125222022 cites W2147703657 @default.
• W2125222022 cites W2150610623 @default.
• W2125222022 cites W2153441442 @default.
• W2125222022 cites W2154034169 @default.
• W2125222022 cites W2160426586 @default.
• W2125222022 cites W2165909321 @default.
• W2125222022 cites W2167731692 @default.
• W2125222022 cites W2216806740 @default.
• W2125222022 cites W2284051918 @default.
• W2125222022 cites W2317089634 @default.
• W2125222022 cites W2321504086 @default.
• W2125222022 cites W2321545438 @default.
• W2125222022 cites W2324402283 @default.
• W2125222022 cites W2335524308 @default.
• W2125222022 cites W2908050222 @default.
• W2125222022 cites W4232245757 @default.
• W2125222022 cites W4241292359 @default.
• W2125222022 cites W4248432835 @default.
• W2125222022 cites W4256662408 @default.
• W2125222022 cites W4366444583 @default.
• W2125222022 cites W2065926725 @default.
• W2125222022 doi "https://doi.org/10.1002/14651858.cd008989.pub3" @default.
• W2125222022 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4164463" @default.
• W2125222022 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26490945" @default.
• W2125222022 hasPublicationYear "2015" @default.
• W2125222022 type Work @default.
• W2125222022 sameAs 2125222022 @default.
• W2125222022 citedByCount "64" @default.
• W2125222022 countsByYear W21252220222012 @default.
• W2125222022 countsByYear W21252220222013 @default.
• W2125222022 countsByYear W21252220222014 @default.
• W2125222022 countsByYear W21252220222015 @default.
• W2125222022 countsByYear W21252220222016 @default.
• W2125222022 countsByYear W21252220222017 @default.
• W2125222022 countsByYear W21252220222018 @default.
• W2125222022 countsByYear W21252220222019 @default.
• W2125222022 countsByYear W21252220222020 @default.

• next